[go: up one dir, main page]

WO2004009559A3 - Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents - Google Patents

Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents Download PDF

Info

Publication number
WO2004009559A3
WO2004009559A3 PCT/CA2003/001082 CA0301082W WO2004009559A3 WO 2004009559 A3 WO2004009559 A3 WO 2004009559A3 CA 0301082 W CA0301082 W CA 0301082W WO 2004009559 A3 WO2004009559 A3 WO 2004009559A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
ictogenic
methods
dihydrouracil
epileptogenic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001082
Other languages
French (fr)
Other versions
WO2004009559A2 (en
Inventor
Kathryn A Jones
Donald F Weaver
Kathryn E Tiedje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Priority to AU2003249812A priority Critical patent/AU2003249812A1/en
Publication of WO2004009559A2 publication Critical patent/WO2004009559A2/en
Publication of WO2004009559A3 publication Critical patent/WO2004009559A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent or treat ictogenesis, epileptogenesis, or epileptogenesis-associated conditions. Methods for preparing the compounds of the invention are also described. Particularly preferred compounds of the invention include Formula 1 as described herein.
PCT/CA2003/001082 2002-07-18 2003-07-18 Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents Ceased WO2004009559A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003249812A AU2003249812A1 (en) 2002-07-18 2003-07-18 Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39715702P 2002-07-18 2002-07-18
US60/397,157 2002-07-18

Publications (2)

Publication Number Publication Date
WO2004009559A2 WO2004009559A2 (en) 2004-01-29
WO2004009559A3 true WO2004009559A3 (en) 2004-04-01

Family

ID=30771012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001082 Ceased WO2004009559A2 (en) 2002-07-18 2003-07-18 Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents

Country Status (2)

Country Link
AU (1) AU2003249812A1 (en)
WO (1) WO2004009559A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678577A1 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2009017664A1 (en) 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
US8592409B2 (en) 2008-01-24 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009102428A2 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ES2421537T3 (en) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Cyclic 11beta-hydroxysteroid dehydrogenase 1 inhibitors
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
JP5696037B2 (en) 2008-05-01 2015-04-08 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
CA2723032A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2730499A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
MA33216B1 (en) 2009-04-30 2012-04-02 Boehringer Ingelheim Int CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
MX2013004699A (en) 2010-11-02 2013-05-22 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS.
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
PT3319939T (en) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Hydantoin containing deoxyuridine triphosphatase inhibitors
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) * 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
WO2018220762A1 (en) * 2017-05-31 2018-12-06 大塚製薬株式会社 Pyrimidine compound
CN113166076A (en) 2018-11-30 2021-07-23 大塚制药株式会社 Heterocyclic compounds for the treatment of epilepsy
JP6870064B2 (en) * 2018-11-30 2021-05-12 大塚製薬株式会社 Pharmaceutical use of pyrimidine compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588729A (en) * 1984-05-16 1986-05-13 Kyowa Hakko Kogyo Co., Ltd. Treating convulsions with dihydrouracil derivatives
JPS61236724A (en) * 1985-04-13 1986-10-22 Kyowa Hakko Kogyo Co Ltd Antispasmodic composition
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588729A (en) * 1984-05-16 1986-05-13 Kyowa Hakko Kogyo Co., Ltd. Treating convulsions with dihydrouracil derivatives
JPS61236724A (en) * 1985-04-13 1986-10-22 Kyowa Hakko Kogyo Co Ltd Antispasmodic composition
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002261204, retrieved from STN accession no. 1987:107921 Database accession no. 1987:107921 *

Also Published As

Publication number Publication date
AU2003249812A1 (en) 2004-02-09
WO2004009559A2 (en) 2004-01-29
AU2003249812A8 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO1998040055A3 (en) Anti-epileptogenic agents
WO2002083651A3 (en) Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2002073208A3 (en) Anti-epileptogenic agents
AP1869A (en) b2- Adrenergic receptor agonists.
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2002064594A3 (en) 6-substituted pyrido-pyrimidines
YU42302A (en) Beta2-adrenergic receptor agonists
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
WO2001062726A3 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
NO20022655L (en) <Beta> -2-adrenergic receptor agonists
WO2005046603A3 (en) Pyridine compounds
WO2001006989A3 (en) Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2002076976A3 (en) Rho-kinase inhibitors
WO2002076977A3 (en) Rho-kinase inhibitors
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO2004080391A3 (en) Novel antibacterial agents
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
WO2001098279A3 (en) Bis-arylsulfones
WO2005099702A3 (en) R(-)-11-hydroxyaporphine derivatives and uses thereof
WO2004093807A3 (en) Somatostatin vectors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP